Loading clinical trials...
Loading clinical trials...
Blood Flow Restriction in Older Adults. A Randomised Single-blind Clinical Trial
Introduction. From the age of 80 onwards, more than 50% of people suffer from sarcopenia. The loss of muscle strength leads to a loss of muscle power, impairing functionality and preventing the correct performance of activities of daily living. Objective. To analyse the efficacy of blood flow restriction in older adult patients by evaluating changes in the variables muscle power and strength, physical condition and functionality of the lower limbs. Material and method. Randomised single-blind clinical study. Thirty-six older adults will be recruited and randomised to the experimental and control groups. The intervention will have a duration of 4 weeks, with 2 weekly sessions. The intervention will consist of an intervention by performing 3 quadriceps strength exercises, with a 40% restriction. The primary variable of the study will be muscle power (Sit To Stand 5 times) and the secondary variables will be muscle strength (dynamometry), physical condition (Timed Up and Go) and functionality and autonomy (Barthel index)
Age
65 - 80 years
Sex
ALL
Healthy Volunteers
Yes
Universidad Católica San Antonio de Murcia
Murcia, Spain
Start Date
March 12, 2025
Primary Completion Date
April 13, 2025
Completion Date
April 15, 2025
Last Updated
April 4, 2025
18
ESTIMATED participants
Blood flow restriction training
OTHER
Lead Sponsor
Universidad Católica San Antonio de Murcia
NCT07052422
NCT02063113
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02405975